Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes | NEJM
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care | Diabetes Technology & Therapeutics
Sanofi and Lexicon collaborate on sotagliflozin
Summary of cardiovascular outcome trials with sodium-glucose... | Download Scientific Diagram
Sotagliflozin with Insulin therapy prevents DKA in young Type 1 Diabetics: Study
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure | 2 Minute Medicine
Early Use of Sotagliflozin Provides Benefits for People With Type 2 Diabetes With Chronic Kidney Disease or Heart Failure | ADA
SCORED : Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk – My Endo Consult
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials | The BMJ
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text
JDRF-T1D Win: Zynquista Approved in Europe for Type 1 Diabetes
Sotagliflozin | Lexicon Pharmaceuticals, Inc.
Herzinsuffizienz | Sotagliflozin bei Diabetes mellitus Typ 2 und Herzinsuffizienz | springermedizin.de
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials | The BMJ
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment - ScienceDirect
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in overweight/obese patients with type 1 diabetes: addressing unmet needs as adjunct therapy to insulin - Media Centre | EASD
Sotagliflozin für Typ-1-Diabetes zugelassen
sotagliflozin
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? | SpringerLink
Sotagliflozin reduces deaths, time spent in hospital for some patients with diabetes
The inTandem 2 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes - Media Centre | EASD
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text
